TGM s Offer to Focus shareholders is 2 TGM shares for every 1 Focus share on issue as at 21 December 2021. Further details of the Offer and the implications for Focus shareholders (including the conditions to the Offer) are set out in the Bidder s Statement.
Wize Pharma and Cosmos Capital enter into Bid Implementation Agreement
USA - English
- Cosmos Capital, a digital infrastructure provider, to become publicly traded through a business combination with Wize
- The combined company is expected to have approximately US$5 million in cash and cash equivalents at closing
News provided by
Share this article
HOD HASHARON, Israel, and SYDNEY, Dec. 30, 2020 /PRNewswire/
Wize Pharma, Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, and Cosmos Capital Limited, a leading digital infrastructure provider based in Sydney, Australia, today announced that they have entered into a bid implementation agreement ( BIA ), whereby Wize has agreed to make an off-market takeover offer to acquire all of the outstanding shares of Cosmos, subject to satisfaction of various closing conditions set forth in the BIA, resulting in Cosmos becoming a wholly-owned subsidiary of Wize.